Armata Pharmaceuticals Inc ARMP Fundamentals and Key Ratios

Armata Pharmaceuticals Inc. (ARMP) Fundamentals


Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

SHARE INFORMATION
Market Cap	$ 103,373,859
Shares Outstanding	36,144,706
Float	10,735,180
Percent Float	29.7%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 1,168,000
Latest Fiscal EPS	$ -0.97
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	36
Institutional Holdings Date	2023-01-31
Institutional Bought Previous 3 Months	16,633
Institutional Holdings Percent	5.1%
Institutional Sold Previous 3 Months	259,820
Insider Holdings Date	2023-01-31
Insider Bought Previous 3 Months	-
Insider Holdings Percent	1.7
Insider Sold Previous 3 Months	-
Insider Shares Owned	599,120

TRADING INFO
52 Week High	$ 5.79
52 Week Low	$ 0.83
52 Week High Change	$ -39.79
21 Day Moving Average	$ 2.5465
21 Day Extended Moving Average	$ 2.6366
50 Day Moving Average	$ 2.0638
50 Day Extended Moving Average	$ 2.4456
200 Day Moving Average	$ 3.4408
200 Day Extended Moving Average	$ 3.2292
10 Day Average Volume	23,715
20 Day Average Volume	20,602
30 Day Average Volume	24,337
50 Day Average Volume	25,041
Alpha	-0.002852
Beta	1.1782
Standard Deviation	0.275800
R2	0.053240
7 Day Price Change	$ -0.43
7 Day Percent Change	-13.07%
21 Day Price Change	$ 0.66
21 Day Percent Change	30.0%
30 Day Price Change	$ 1.76
30 Day Percent Change	160.0%
Month to Date Price Change	$ -0.12
Month to Date Percent Change	-4.03%
Quarter to Date Price Change	$ 1.62
Quarter to Date Percent Change	130.65%
180 Day Price Change	$ -1.37
180 Day Percent Change	-32.39%
200 Day Price Change	$ -1.34
200 Day Percent Change	-31.9%
Year to Date Price Change	$ 1.62
Year to Date Percent Change	130.65%

PROFITABILITY
EBIT Margin	-2,854.3%
EBITDA Margin	-2,712.6%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 0
Revenue Per Share	$ 0.00
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	3.30
Total Debt To Equity	0.90
Int Coverage	-14,726.50
Current Ratio	4.70
Leverage Ratio	1.90
Quick Ratio	3.90
Long Term Debt To Capital	0.45

VALUATION MEASURES
PE Ratio	-2.80
Enterprise Value	$ 117,437,859
Price to Sales	0.00
Price to Free Cash	-4.20
PE High Last 5 Years	-0.30
Price To Book	2.30
Price To Cash Flow	0.00
PE Low Last 5 Years	-2.00
Price to Tangible Book	3.30

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-48.17
Return on Equity	-94.18
Return on Capital	-53.95

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	Ernst & Young LLP
CEO	Brian Varnum
Emplyoees	71
Last Audit	UE
CIK	0000921114
Industry	Biotechnology
Sector	Healthcare
NAICS	Biological Product (except Diagnostic) Manufacturing(325414)

CONTACT INFO
Address	4503 Glencoe Avenue Marina del Rey, CA 90292
Website	https://www.armatapharma.com
Facsimile	+1 310 665-2963
Telephone	+1 858 829-0829
Email	ir@armatapharma.com

Quotes:

IHub:

ARMP

Armata Pharmaceuticals Inc. (ARMP) Fundamentals

Armata Pharmaceuticals Inc. (ARMP) Key Ratios

Armata Pharmaceuticals Inc. (ARMP) Profile